Biogen Raising Minority Stake in Samsung Bioepis in $672M Deal

Biogen will pay Samsung Bioepis KRW 748.6 billion ($673.4 million) to increase its minority stake in biosimilars developer Samsung Bioepis, a joint venture of Biogen and Samsung BioLogics.Biogen said it has exercised its option to purchase additional shares of the joint venture, which will raise its minority stake from approximately 5.4% to approximately 49.9%. Biogen will buy 9,226,068 shares valued at KRW 2.26 trillion ($2 billion), in a deal expected to occur on September 28, Samsung Bioepis